Why Is TANDEM DIABETES CARE (TNDM) Stock Up Today?
By the Top Tier Newswire AI Desk · November 18, 2026 at 9:43 AM ET · reviewed against 7 wire stories
TANDEM DIABETES CARE (TNDM) is up +5.42% in the latest session. Our newswire has captured 7 stories on TNDM across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 62/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Tandem Diabetes Care (TNDM) shares rose 5.42% to $17.99, driven primarily by an upgrade from Stifel and recent regulatory approvals. The stock gap up at the open following Stifel’s move to a Buy rating with a $26.00 price target.
What Happened
Stifel upgraded Tandem Diabetes Care to Buy from Hold, raising its price target to $26.00. The firm cited the company’s product pipeline, share gains, and improving margins as key drivers for the positive outlook. This action followed recent regulatory milestones, including FDA clearance for the Tubeless Tandem Mobi system and Health Canada approval for a t:slim X2 insulin pump license amendment. Additionally, the company appointed Jeannette Bankes as President and CEO. Barclays also recently adjusted its price target for the stock.
What The Data Shows
The stock opened at $17.99, a 5.5% gap from the prior close of $17.06. Intraday activity saw a session high of $18.29 and a low of $17.50, both recorded at 9:30 AM ET, with the last trade at $18.15. Volume stood at 0.2M shares, which is 0.1x the three-month daily average. Fundamentals show a market cap of $1.3B, with the company remaining unprofitable at a trailing twelve-month EPS of -0.72. Revenue grew 6.8% over the same period, while the net margin stood at -4.6%. The stock has a beta of 1.60 and trades within a 52-week range of $12.26 to $29.65. Over the last eight sessions, the stock moved 0.9% from $16.91 to $17.06. Recent SEC filings indicate one insider sale by Christopher J. Twomey on October 27, 2026, totaling $33K. Congressional disclosures show three buys and one sell in the last 90 days, including a purchase by Rep. Gilbert Ray Cisneros, Jr. in September 2026.
What To Watch
Investors will monitor the company’s progress in executing its product pipeline and integrating new leadership. The upcoming earnings date is not specified in the current data, but coverage breadth remains active with seven stories from four sources in the last 36 hours.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Stifel upgrades Tandem Diabetes stock rating on product pipeline
Stifel upgrades Tandem Diabetes stock rating on product pipeline
2d agoGuruFocusBULLISH 67Analyst
Stifel Upgrades Tandem Diabetes (TNDM) to Buy, Raising Price Target to $26
2d agoThe FlyBULLISH 64Analyst
Stifel upgrades Tandem to Buy, notes share gains and improving margins
2d agoThe FlyBULLISH 64Analyst
Tandem Diabetes upgraded to Buy from Hold at Stifel
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →